RNA-based therapy brings new hope for an incurable blood cancer
Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia...
View ArticleIbrutinib has 'unprecedented' impact on mantle cell lymphoma
An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.
View ArticleExperimental drug combination selectively destroys lymphoma cells
Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an...
View ArticleResearchers exploit cancer's faulty defence mechanism
Researchers in Germany have found a new way to exploit the differences between cancer cells and normal cells that could lead to new treatments.
View ArticleDrug shows surprising efficacy as treatment for chronic leukemia, mantle cell...
Two clinical studies published in the New England Journal of Medicine with an accompanying editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective, targeted treatment...
View ArticleIbrutinib continues strong showing against mantle cell lymphoma
In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed...
View ArticleNew drug treatment for form of lethal cancer is approved
A new drug has been approved to battle mantle cell lymphoma, an aggressive cancer often fatal because of its resistance to treatment, after a study led by a Hackensack University Medical Center...
View ArticleGenome of one of the most aggressive lymphomas sequenced
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the...
View ArticleImbruvica approved for mantle cell lymphoma
(HealthDay)—Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL), a rare but aggressive form of blood cancer.
View ArticleStudy finds pill may represent promising treatment for stubborn blood cancers
A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma patients running out of treatment options for their aggressive, treatment-resistant disease,...
View ArticleChemo-free treatment a possibility for leukemia / lymphoma
Patients with terminal forms of leukaemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side...
View ArticleStudy identifies rational drug combinations that may overcome mantle cell...
Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas that fail to respond to treatment with the anticancer drug ibrutinib (Imbruvica) or initially respond but then stop...
View ArticleStudy identifies potential drug combination for mantle cell lymphoma and...
Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic...
View ArticleFunding to investigate an alternative to chemotherapy
Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a...
View ArticleNew disease mechanism discovered in lymphoma
Programmed cell death is a mechanism that causes defective and potentially harmful cells to destroy themselves. It serves a number of purposes in the body, including the prevention of malignant tumor...
View ArticleRational drug combinations that may overcome mantle cell lymphoma resistance...
Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphomas that fail to respond to treatment with the anticancer drug ibrutinib (Imbruvica) or initially respond but then stop...
View ArticleCelgene will buy drug developer Receptos for $7.32 billion
Cancer drug maker Celgene said it will buy Receptos for $7.32 billion in cash, gaining a drug Receptos is studying as a treatment for multiple sclerosis and ulcerative colitis.
View ArticleEndoscopic evaluation advised in non-Hodgkin's lymphoma
(HealthDay)—For elderly adults diagnosed with non-Hodgkin's lymphoma, endoscopic evaluation may be recommended even in the absence of gastrointestinal symptoms, according to a letter to the editor...
View ArticleNew drug combination suggests promising treatment for mantle cell lymphoma
A combination therapy lacking many of the debilitating effects of traditional cancer treatment effectively manages mantle cell lymphoma, shrinking the aggressive and incurable malignancy and inducing...
View ArticleLenalidomide plus rituximab produces durable responses in mantle cell...
New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell...
View ArticleHigh response rates, long-term remissions in Penn trials of personalized cell...
Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own...
View ArticleIbrutinib: Indication of added benefit in one of three therapeutic indications
Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma...
View ArticleOverall survival in mantle cell lymphoma up with deferred Tx
(HealthDay)—For patients with mantle cell lymphoma (MCL), deferred therapy seems safe and is an independent predictor of overall survival, according to a study published online May 6 in Cancer.
View ArticleDrug combination yields results in patients with forms of leukemia or lymphoma
A combination of two targeted agents - one approved by the Food and Drug Administration and one undergoing testing - has demonstrated safety as well as encouraging signs of effectiveness in a phase 1...
View ArticleCancer researchers look at resistance to targeted therapy in mantle cell...
Today some patients suffering with mantle cell lymphoma, a type of blood cancer, can be treated with a pill called Ibrutinib, forgoing conventional chemotherapy. However, many are developing a...
View ArticleStudy links mutations in notch gene to role in B cell cancers
Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors,...
View ArticleAstraZeneca wins US approval for lymphoma drug
U.S. regulators have approved a new treatment for people with a rare form of non-Hodgkin lymphoma.
View ArticleTargeted oral therapy combo safe, effective for chronic lymphocytic leukemia
Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor, a newer class of drugs shown to improve the survival of patients with chronic lymphocytic leukemia (CLL) and mantle cell...
View Article